ALK and anaplastic large cell lymphoma: Our evaluations of the efficacy of OTX015, a new BRD inhibitor in early clinical development, in a panel of ALK+ ALCL cell lines revealed two key points; firstly that OTX015 had mainly cytostatic activity leading to G1 cell cycle arrest of ALK+ ALCL cells and inducing down-regulation of MYC and other transcription factors such as E2F1, as well as their target genes, and secondly that ibrutinib and GANT61 are synergistic with OTX015 leading to cell growth inhibition and cell death of ALKi resistant ALCL cells.